As life sciences investors shy away from drug development and opt for lower-risk devices and diagnostics, what can Europe learn from Israel’s experience?
As governments direct stimulus packages towards science and research, don’t forget the current crop of spin-outs who face extinction in a frozen capital market, writes Nuala Moran.
The EIT has published the call for proposals for its first two or three Knowledge and Innovation Communities, which are to be selected by the end of January 2010.
Helsinn Holding SA, a privately-owned pharmaceutical company, is to establish a centre of excellence in R&D of oral solid dosage at its existing site in Dublin.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.